Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 91

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 1
Chunk 91
---
 contribute to profitable sales growth.

46

Other Operating Expenses

The following provides a summary of certain of our other operating expenses, which are excluded by management for purposes of evaluating operating performance; refer to Additional Information for a further description.

Amortization Expense

During the second quarter of 2025, Amortization expense increased $12 million, or 6 percent, compared to the prior year period. In the first six months of 2025, Amortization expense increased $18 million, or 4 percent, compared to the prior year period.

Intangible Asset Impairment Charges

In 2025, we recorded Intangible asset impairment charges of $46 million in the second quarter and first six months. In 2024, we recorded Intangible asset impairment charges of $276 million in the second quarter and first six months. The impairment charges recorded in 2024 were associated with amortizable intangible assets established in connection with our acquisitions of Cryterion Medical, Inc. (Cryterion) and Devoro Medical, Inc. (Devoro), which were integrated into our Electrophysiology and Peripheral Interventions business units, respectively. Intangible assets acquired from Cryterion were impaired due to strong commercial adoption of our Farapulse™ Pulsed Field Ablation System and the resulting lower revenue projections and cannibalization of our cryoablation business in major markets like the U.S. Intangible assets acquired from Devoro were impaired following management's decision to cancel the related program in the second quarter of 2024.

Refer to Note C – Goodwill and Other Intangible Assets to our unaudited consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q and Critical Accounting Policies and Estimates contained in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of our most recent Annual Report on Form 10-K for additional details and a discussion of key assumptions used in our intangible asset impairment testing and future events that could have a negative impact on the recoverability of our intangible assets.

Contingent Consideration Net Expense (Benefit)

Three Months EndedJune 30,Six Months EndedJune 30,(in millions)2025202420252024Net charges (benefit)$(5)$2 $0 $18 Payments for prior acquisitions following the achievement of associated milestones62 — 62 133 

Refer to Note B – Acquisitions and Strategic Investments to our unaudited consolidated financial